Literature DB >> 10745621

Epstein-Barr virus--associated diseases in humans.

K Kawa1.   

Abstract

It has been known for 30 years that Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, is the etiologic agent of acute infectious mononucleosis and is closely associated with the genesis of Burkitt's lymphoma and undifferentiated nasopharyngeal carcinoma. Recent studies have demonstrated that EBV is also implicated in a variety of other diseases, such as EBV-associated hemophagocytic syndrome, chronic active EBV infection, T-cell lymphoma, natural killer cell leukemia/lymphoma, lymphoproliferative diseases in immunocompromised hosts, Hodgkin's disease, pyothorax-associated B-cell lymphoma, smooth-muscle tumors, and gastric carcinoma. Thus, the virus continues to attract worldwide attention, and it is now appropriate for a reappraisal of the relation between EBV and human diseases. This review summarizes the recent progress in research on EBV and the clinical findings of EBV-associated diseases and provides a basis for the development of new therapeutic strategies.

Entities:  

Mesh:

Year:  2000        PMID: 10745621

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  34 in total

1.  Strong minor groove base conservation in sequence logos implies DNA distortion or base flipping during replication and transcription initiation.

Authors:  T D Schneider
Journal:  Nucleic Acids Res       Date:  2001-12-01       Impact factor: 16.971

2.  Posttransplantation Epstein-Barr viral meningitis in a patient with chronic myelogenous leukemia.

Authors:  H Kanamori; S Fujisawa; S Yamaji; M Tanaka; N Tomita; K Fujimaki; Y Ishigatsubo
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

3.  Sequential quantification of Epstein-Barr virus DNA in a case of Epstein-Barr virus-associated hemophagocytic syndrome.

Authors:  Toru Takahashi; Eiichi Oeda; Yutaka Sato; Yukio Tanizawa
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

4.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

Review 5.  Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.

Authors:  Emily Cousins; John Nicholas
Journal:  Recent Results Cancer Res       Date:  2014

6.  Epstein-Barr virus latent membrane protein 1 increases calcium influx through store-operated channels in B lymphoid cells.

Authors:  Olivier Dellis; Atousa Arbabian; Béla Papp; Martin Rowe; Irène Joab; Christine Chomienne
Journal:  J Biol Chem       Date:  2011-03-30       Impact factor: 5.157

Review 7.  How we treat chronic active Epstein-Barr virus infection.

Authors:  Akihisa Sawada; Masami Inoue; Keisei Kawa
Journal:  Int J Hematol       Date:  2017-02-16       Impact factor: 2.490

8.  Detection of Helicobacter pylori and Chlamydia pneumoniae genes in primary orbital lymphoma.

Authors:  Chi-Chao Chan; Defen Shen; Manabu Mochizuki; John A Gonzales; Hunter K L Yuen; Yan Guex-Crosier; Phuc Lehoang
Journal:  Trans Am Ophthalmol Soc       Date:  2006

9.  Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection.

Authors:  Masao Hagihara; Takahide Tsuchiya; Osamu Hyodo; Yoko Ueda; Kei Tazume; Aya Masui; Ayako Kanemura; Fumiaki Yoshiba; Shinji Takashimizu; Shohei Matzusaki; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 10.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.